Injective Price Surges 17% Amid ETF Filing and Phantom Integration

The price of Injective (INJ) surged by over 17% as it benefits from fresh institutional and ecosystem developments. The broader crypto market is also moving higher, contributing to INJ's rally. A proposed ETF from 21Shares, filed in an S-1 update, outlines a potential staking allocation of 40%-60% of the fund's INJ holdings.

The ETF filing introduces a staking strategy for its proposed Injective investment product. The fund aims to stake between 40% and 60% of its INJ holdings, with the allocation adjustable based on liquidity requirements. This could allow the fund to generate additional yield from its INJ holdings while maintaining flexibility around liquidity management.

Injective has also integrated with Phantom, a leading wallet in the Solana ecosystem. This integration enables users to hold, trade, borrow, and exchange tokens through the wallet's application and web extension. The move supports Injective's broader focus on financial infrastructure, cross-chain accessibility, and tokenized assets.

While these developments strengthen Injective's narrative, the long-term impact depends on regulatory progress, real user adoption, and sustained demand for INJ. A continuation of the rally would require sustained volume and broader market support rather than a temporary reaction to ecosystem headlines.